Press release

Advertisement

REGULATED INFORMATION
INSIDE INFORMATION
Wednesday 3 December 2025 - 7:30 a.m.

Care Property Invest
Public limited liability company (société anonyme/naamloze vennootschap),
Public Regulated Real Estate Company (Société Immobilière Réglementée (SIR) / Gereglementeerde Vastgoedvennootschap (GVV)) under Belgian Law
Registered Office: 3 Horstebaan, 2900 Schoten
Companies Registration No. 0456.378.070 (LPR Antwerp, Antwerp division)
(Hereinafter also referred to as the 'Company')

Public offering of subscription to new shares regarding a capital increase in cash within the authorised capital with irreducible allocation rights for an amount of maximum eur 55.483.249,50, to finance the acquisition of 9 healthcare real estate sites

The offering consists of a public offering to subscribe to the new shares in Belgium and will be followed by a private placement of the remaining shares with a number of "backstoppers", who have irrevocably committed to subscribe for the remaining shares for a total amount of eur 55,5 million

Request for admission to trading of (i) the new shares, as of their issuance, and (ii) the irreducible allocation rights, during the subscription period, on the regulated market of Euronext Brussels

Warning: An investment in shares and/or trading of irreducible allocation rights involves significant risks. Investors are advised to review the information document (and the information referenced therein), and in particular the risk factors described in section 8 of the information document, before investing in new shares or trading irreducible allocation rights. Any decision to invest in new shares or to trade irreducible allocation rights in connection with the offering must be based on all the information provided in the information document (and the information referenced therein, including but not limited to the annual financial report for fiscal year 2024, the half-yearly financial report for financial year 2025, the interim statement for the third quarter of financial year 2025, and the press releases regarding the announcement of the transaction and the Acquisition (as defined below)). Potential investors must be able to bear the economic risk of an investment in shares or the trading of irreducible allocation rights and to accept a full or partial loss of their investment.

Schoten, Belgium - Wednesday 3 December 2025

Care Property Invest NV ("**CP Invest**" or the "**Company**") announces a capital increase by means of a contribution in cash within the authorised capital with cancellation of the statutory preferential subscription rights, insofar as necessary, partly for the benefit of the Backstoppers (as defined below), and with allocation of irreducible allocation rights to the existing shareholders.

Under the capital increase, it is the intention to issue a maximum of 5.284.119 new shares for a maximum amount of up to EUR 55.483.249,50.

The issue price, as set by the Company, in consultation with the Joint Global Coordinators, is EUR 10,5 per new share, representing a discount of 5,41% compared to the closing price of the shares on 2 december 2025 (which amounted to EUR 12,02), adjusted to take into account the estimated value of coupon no. 21 which will be detached on 3 december 2025 (after market close), i.e. EUR 11,10 after such adjustment.

7 irreducible allocation rights give the right to subscribe to 1 new share.

Detachment of coupon no. 20, that respresents the irreducible allocation right: 3 December 2025 (after trading hours).

Detachment of coupon no. 21, that respresents the right to receive gross dividend for the period from 1 January 2025 up to and including 3 December 2025, to which the new shares will not be entitled: 3 December 2025 (after trading hours).

Subscription period for the new shares through exercising irreducible allocation rights: from Thursday 4 December 2025 (9:00 a.m.) (Belgian time) until Thursday 10 December 2025 (4:00 p.m.) (Belgian time).

All new shares that are not subscribed for through the valid exercise of irreducible allocation rights (the "**Remaining Shares")** will, by way of a private placement, be offered to Sakolaki[1], de heer Dirk Van den Broeck, Konrad Invest BV[2] and Korian Belgium [3] (the "**Backstoppers**") at the same issue price of EUR 10,5. The Backstoppers have irrevocably undertaken to subscribe for the Remaining Shares at the aforementioned issue price for an aggregate amount of EUR 55,5 million, each respectively for EUR 5 million, EUR 2 million, EUR 42 million and EUR 6,5 million. This ensures full coverage of the offering and eliminates the risk of insufficient subscription. The irreducible allocation rights that were not exercised during the subscription period (or are deemed as such) will not be converted into scrips, will not be sold or placed, and will therefore lapse and have no value. The Backstoppers' subscription commitments are currently still subject to the condition that the transaction takes place by 31 December 2025.The Backstoppers have undertaken not to transfer the Remaining Shares subscribed by them during a period of 180 days as from the date following completion of the capital increase, subject to customary exceptions.

[1] A public limited liability company incorporated and existing under Belgian law, having its registered office at Natiënlaan 265, box 21, 8300 Knokke-Heist (Belgium) and registered with the Crossroads Bank for Enterprises under number 0448.192.656 (RLE Ghent, Bruges) ("**Sakolaki**")

[2] A private limited liability company incorporated and existing under Belgian law, having its registered office at Winkelom 83B, box 1, 2440 Geel (Belgium) and registered with the Crossroads Bank for Enterprises under number 656.636.154 (RPR/RPM Antwerp, Turnhout ("**Konrad Invest BV**")

[3] A public limited liability company incorporated and existing under Belgian law, Satenrozen 1B, 2550 Kontich (Belgium), and registered with the Crossroads Bank for Enterprises under number 0869.769.702 (RPR/RPM Antwerp, Antwerp)("**Korian Belgium**")

Belfius Bank NV (in cooperation with Kepler Cheuvreux SA) and KBC Securities NV act as **Joint Global Coordinators en Underwriters**.

Offering

Every existing shareholder will receive one irreducible allocation right per existing share held at market close on 3 December 2025. The irreducible allocation right will be represented by coupon no. 20 and will be tradable on Euronext Brussels during the subscription period, i.e., from 4 December 2025 (9:00 a.m.) (Belgian time) until 10 December 2025 (4:00 p.m.) (Belgian time).

Existing shareholders holding irreducible allocation rights and other holders of irreducible allocation rights can subscribe to the new shares from 4 December 2025 (9:00 a.m.) (Belgian time) up to and including 10 December 2025 (4:00 p.m.) (Belgian time), under the terms and conditions set out in the information document, at an issue price of EUR 10,5 per new share and at a ratio of 1 new share(s) for 7 irreducible allocation rights.

The offering relates to a maximum of 5.284.119 new shares that will have the same rights as the existing shares, it being understood that they will not participate in the Company's results for the period from 1 January 2025 up to and including 3 December 2025, but will participate in the Company's results as from 4 December 2025.

The capital increase was decided within the framework of the authorised capital.

Reasons for the offering and use of proceeds

The main objective of the offering is to finance the acquisition of shares in a company holding a portfolio of nine healthcare real estate sites, eight located in Flanders and one in Wallonia, representing a total investment value of approximately EUR 142.6 million and an expected annual rental income of approximately EUR 8.2 million, which was completed on 2 December 2025 (the "**Acquisition**"). The portion of the Acquisition's investment value not covered by the offering (approximately EUR 87.1 million, assuming full subscription to the offering) will be financed by the Company through, on the one hand, new borrowings under existing credit facilities and, on the other hand, the assumption of the ongoing loan agreements and obligations of the company subject to the Acquisition. The buildings were constructed or renovated between 2010 and 2025. All healthcare real estate sites are currently operated by Korian Belgium (further information is available in the press release dated 3 December 2025, accessible on the Company's website via the following link: https://carepropertyinvest.be/en/investments/press-releases/.

The Acquisition represents a strategic, value-creating investment enabling the Company to restore its portfolio to a growth trajectory by increasing portfolio size and revenue by at least ten percent (10%), in line with the Company's strategy focused on medium-term EPS-growth[4]. Furthermore, the Acquisition significantly enhances the quality of the Company's real estate portfolio, both in terms of energy efficiency and average asset age, as well as the financial metrics of its operators, including occupancy rate and effort rate. It also contributes to mitigating the dilution effects of the historical portfolio and its gradual expiry. The anticipated portfolio growth and increase in the number of issued shares will additionally support greater liquidity in the Company's shares, potentially enhancing its attractiveness to institutional investors.

---

[4] 'Earnings per share'

In addition, the offering will enable the Company to maintain a debt ratio of no more than 50% (this does not exclude the possibility that it may be exceeded for short periods). The maximum permitted leverage under the Company's banking covenants is 60%. The Company's pro forma debt ratio (in accordance with Article 13, §1, 2° of the RREC Royal Decree), assuming full subscription to the offering and taking into account the irrevocable and unconditional commitments of the Backstoppers, will amount to 49,60% following completion of the Acquisition[5]. The EPRA LTV, which amounted to 46.56% as at 30 September 2025, will on a pro forma basis amount to 47.79% after completion of the Acquisition and if the Offering is fully subscribed.[6]
The gross proceeds of the offering will also be used to pay the transaction costs related to the offering and the admission to trading and listing on Euronext Brussels; these transaction costs also include fees, commissions and expenses payable to the Underwriters. The net proceeds of the offering, assuming full subscription, are estimated at approximately EUR 54.383.250.

The Company cannot predict with certainty all uses of the proceeds of the transaction, nor the amounts it will allocate to the purposes described above. Consequently, the Company will retain maximum flexibility in the application of the net proceeds of the transaction and may adjust the allocation depending on circumstances. The Company reserves the right to proceed with a capital increase for a lower amount. No minimum amount has been set for the offering.

Dividend entitlement

All new shares will be issued in euro, in accordance with Belgian law and will be ordinary shares, of the same type as the existing shares, fully paid up, with voting rights and without nominal value.

The new shares will have the same rights as the existing shares, it being understood that as a result of the detachment of coupon no. 21 on 3 December 2025 (after market close), they will not participate in the Company's results for the period from 1 January 2025 up to and including 3 December 2025, but will participate in the Company's results as from 4 December 2025.

Barring unforeseen circumstances, the Company foresees a gross dividend for the financial year 2025 of at least EUR 1.00 per share (taking into account the increased number of shares that will participate in the results for the 2025 financial year as a consequence of the offering, (assuming the maximum number of new shares is issued), and earnings per share of EUR 1.16, provided that the new shares will not be entitled to the dividend for the period from 1 January 2025 up to and including 3 December 2025). After subtracting withholding tax of 15% this would result in a net dividend of EUR 0.85 per share. For the financial year 2026, the Company, subject to unforeseen circumstances, anticipates a gross dividend of EUR 1.00 per share (taking into account the increased number of shares that will participate in the results for the 2026 financial year as a consequence of the offering, assuming the maximum number of new shares is issued). The prior is obviously subject to the effective results for the financial years 2025 and 2026 and the approval of dividend distributions by the general meeting of the Company.

---

[5] Based on the Company's debt ratio as of 30 September 2025 and taking into account (i) an additional financing of EUR 87.1 million resulting from the Acquisition and (ii) a fully subscribed Offering.

[6] Based on the Company's EPRA LTV as of 30 September 2025 and taking into account (i) an additional financing of EUR 87.1 million resulting from the Acquisition and (ii) a fully subscribed Offering.

Issue Price

The issue price amounts to EUR 10,5 per new share and has been determined by the Company in consultation with the Joint Global Coordinators (including after analysing investor feedback received during an extensive market sounding conducted by the Joint Global Coordinators) on the basis of the stock market price of the share on the regulated market of Euronext Brussels and taking into account a discount usually granted for this type of transaction (given the objective of limiting dilution for existing shareholders), and also in light of the valuation of the Company's assets (including its perimeter companies) in accordance with Article 48, 1° of the RREC Law.

The issue price is 5,41% lower than the closing price of the share on the regulated market of Euronext Brussels on 2 December 2025 (which amounted to EUR 12,02), adjusted to take into account the estimated value of coupon no. 21[7] that is being detached on 3 December 2025 (after market close) (i.e., EUR 11,10 after such adjustment). Based on that closing price, the theoretical ex-rights price ("**TERP**") is EUR 11,03, the theoretical value of an irreducible allocation right is EUR 0,075, and the discount of the issue price compared to TERP is 4,76%.

Subscriptions

Subscription applications may be submitted directly at the counters of Belfius Bank NV, KBC Securities NV and KBC Bank NV for investors holding client accounts and/or through any other financial intermediary. There may be costs associated with the exercise and the purchase or sale of irreducible allocation rights. Investors are invited to inform themselves about possible costs charged by their financial intermediaries in this respect.

Shareholders holding their shares in a securities account will automatically be allocated a corresponding number of irreducible allocation rights in the securities account they hold with their financial institution, subject to the restrictions set out in the information document and applicable securities law. Their financial institution will inform them of the procedure for exercising or trading their irreducible allocation rights.

The existing shareholders who hold their shares in registered form, will need to follow the instructions as noted in the notices that they will receive from the Company (subject to applicable securities laws) and through which they will be informed of the total number of irreducible allocation rights they hold and the procedure that they must follow to exercise or trade their irreducible allocation rights.

Irreducible allocation rights

The irreducible allocation right, represented by coupon no. 20 attached to the existing shares, will be detached from the existing shares on 3 December 2025 after the close of trading. The irreducible allocation rights will be tradable on the regulated market of Euronext Brussels under ISIN code BE0970191947 during the subscription period. Those who have not exercised their non-reducible allocation rights at the end of the subscription period, i.e. no later than 10 December 2025 (4 p.m.) (Belgian time), will no longer be able to exercise them after this date.

[7] The Board of Directors of the Company estimates coupon no. 21, which represents the gross dividend for the period from 1 January 2025 up to and including 3 December 2025, at EUR 0.92 per share. This estimate is, of course, subject to the results of the financial year 2025 and the approval by the ordinary general meeting that will decide on the dividend to be distributed in respect of the financial year 2025.

No private placement of scrips

The (i) irreducible allocation rights that were not exercised in a timely and correct manner on the closing date of the subscription period and (ii) registered irreducible allocation rights (x) for which a properly completed and signed subscription form was not received in time, (y) which have not been transferred by (the financial intermediary of) the shareholder (despite any instructions to do so), or (z) for which the total issue price has not been paid in time (and all of which will thereby be qualified as unexercised irreducible allocation rights) will not be converted into scrips, will not be sold or placed, and will therefore lapse and have no value. The Remaining Shares will, in fact, be offered to the Backstoppers at the same issue price as part of a private placement, and the Backstoppers have irrevocably undertaken to subscribe to the Remaining Shares for a total amount of EUR 55.5 million.

Disclosure of the results of the offer

The result of the subscriptions for new shares resulting from the exercise of the irreducible allocation rights as part of the public offering will be announced on 11 December 2025 via a press release on the Company's website.

Payment and delivery of the new shares

Payment for subscriptions to new shares resulting from the exercise of dematerialised non-reducible allocation rights will be made by debiting the subscribers' accounts, with a value date of, in principle, 15 December 2025.

The total issue price for the new shares subscribed for based on registered irreducible allocation rights must have reached (credited) the bank account specified in the letters to the registered shareholders no later than 4 p.m. (Belgian time) on 10 December 2025. This is an absolute requirement in order to be able to proceed with the issue and delivery of the new shares subscribed for by existing shareholders who hold their shares in registered form through the exercise of registered irreducible allocation rights. In order to make sure that this issue price is received on time, the Company advises existing shareholders holding their registered shares to give timely the necessary instructions to their financial institution for this purpose. The Company will refund late payments.

New shares issued on the basis of registered irreducible allocation rights will be included as registered shares in the Company's share register on 15 December 2025. New shares issued on the basis of dematerialised irreducible allocation rights will be delivered in dematerialised form on 15 December 2025.

Listing of the new shares

The new shares will, in principle, be admitted to trading on the regulated market of Euronext Brussels from 15 December 2025. The new shares will be assigned ISIN code BE0974273055, which is the same code as that for the existing shares.

Information document

The information document is available in Dutch and English.

The information document will be made available to investors free of charge at the Company's registered office (Horstebaan 3, 2900 Schoten, Belgium) from 3 December 2025 (before trading hours). The information document will also be made available to investors free of charge at (i) Belfius Bank on its website https://www.belfius.be/CPI2025 (NL and FR) and (ii) KBC Securities on its website https://www.kbc.be/carepropertyinvest2025 (NL, FR and ENG).

The information document can also be consulted from 3 December 2025 (before trading hours) on the Company's website (https://carepropertyinvest.be/en/investments/shareholder-structure/capital-increase/), with access to the above websites being subject to the usual restrictions.

Expected offering timetable

Decision of the board of directors to increase the capital and to determine the issue price / subscription ratio / amount of the offer	3 December 2025 (before trading hours
Filing of the information document with the FSMA and publication on the Company's website	3 December 2025 (before trading hours
Press release announcing the offering, the modalities of the offering and the launch of the subscription period	3 December 2025 (before trading hours)
Detachment of coupon no. 21 which represents the dividend right for the period from 1 January 2025 to 3 December 2025], which will not be allocated to the new shares	3 December 2025 (after trading hours)
Detachment of coupon no. 20 for the exercise of the irreducible allocation right	3 December 2025 (after trading hours)
Trade in shares ex-coupons nos. 21 and 20	4 December 2025
Opening date of the subscription period	4 December 2025 at 9:00 a.m. (Belgian time)
Admission to trading of the irreducible allocation rights on the regulated market of Euronext Brussels	4 December 2025 at 9:00 a.m. (Belgian time)
Deadline by which (i) the Company must receive the subscription forms relating to the registered irreducible allocation rights and (ii) the corresponding issue price must have been received (credited) on the bank account specified in the letter to the registered shareholders	10 December 2025 at 4 p.m. (Belgian time)
Subscription Period Closing Date	10 December 2025 at 4 p.m. (Belgian time)
Suspension of trading of the irreducible allocation rights on the regulated market of Euronext Brussels	10 December 2025 at 4 p.m. (Belgian time)
Allocation of Remaining Shares to the Backstoppers	11 December 2025 (before trading hours)
Publication of the press release on the results of the public offering (and private placement)	11 December 2025 (before trading hours)
Payment date of the new shares subscribed for with dematerialised irreducible allocation rights	15 December 2025
Establishment of the realisation of the capital increase	15 December 2025
Admission to trading of the new shares on the regulated market of Euronext Brussels	15 December 2025
Delivery of the new shares to the subscribers	15 December 2025
Publication of the press release concerning the capital increase and the new denominator for transparency purposes	15 December 2025

The Company can adjust the dates and times of the capital increase and the periods indicated in the above timetable and in the information document. In that case, the Company will notify Euronext Brussels and will inform the investors on this subject through a press release and on the Company's website.

Decision of the committee of independent directors of the Company and assessment by the Company's statutory auditor pursuant to Article 7:97 of the Belgian Companies and Associations Code

Decision of the Company's committee of independent directors (the '**Committee**'):

"The Committee unanimously agrees that the proposed Offer, the proposed Issue Price, the Pre-Commitments sought by the board of directors in that context and the requested allocation of the Remaning Shares in exchange (and the resulting cancellation of the statutory preferential right, insofar as necessary, partly in favour of the Backstoppers, including Dirk Van dan Broeck), is in the interest of the Company and its shareholders.
The contemplated Offering allows the Company to finance the Acquisition partially with equity.
The contemplated Issue Price would represent a discount that is in line with the discounts typically applied in the context of an exempt private placement in the form of an accelerated bookbuild offering ('ABB') to institutional investors, and which is significantly smaller than the discount that is usually granted in a rights issue.
The Pre-Commitments, which would form the basis of the proposed guaranteed allocation of the Remaining Shares, would cover the entire proposed Offer and would completely eliminate the risk of insufficient subscription to the Offer. The Pre-Commitments underlying the allocation of Remaining Shares offer the Company the certainty that (if it chooses to proceed with the Offer) 100% of the shares to be placed in the Offer will be subscribed at the issue price."

Assessment by the Company's statutory auditor:

"Based on our review, performed in accordance with International Standard on Review Engagements 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', nothing has come to our attention that causes us to believe that the accounting and financial information included in the minutes of the Board of Directors and in the opinion of the Committee of Independent Directors, both prepared in accordance with the requirements of Article 7:97 of the BCCA, are not accurate or that that they contain materially significant inconsistencies compared to the information available to us in the context of our engagement. We do not express an opinion on the appropriateness or desirability of the transaction, nor on whether the transaction is lawful and fair ('no fairness opinion')."

published in due course by Care Property Invest NV ("**CPI**" or the "**Company**") in connection with the offering (the "**Information Document**"). Copies of the Information Document will be available upon request at the Company's registered office at Horstebaan 3, 2900 Schoten, Belgium and on the website https://carepropertyinvest.be/en/investments/shareholder-structure/capital-increase and will also be available upon request from Belfius Bank SA/NV and KBC Securities NV.

This information does not contain a solicitation for money, securities, or other considerations and, if sent in response to the information contained herein, will not be accepted.

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that none of these forward-looking statements offers any guarantee of future performance. The Company's actual results may differ materially from those set out by the forward-looking statements. The Company is not obliged to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

The Company's securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**Securities Act**"), or under the laws of any state or other jurisdiction in the United States of America, and may not be offered or sold within the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws. No public offering of securities will be made in the United States of America.

This information does not constitute an offer or invitation to proceed to an acquisition of or subscription for the Company's securities, nor an offer or invitation to proceed to an acquisition of or subscription for the Company's securities in the United States of America, Australia, Canada, Japan, South Africa, Switzerland (except in the context of a private placement of certain securities with "professional clients" as set out below), the United Kingdom (except in the context of a private placement of certain securities with certain qualified investors as set out below) or any other jurisdiction where such offer or invitation is not allowed without registration or qualification under the applicable legislation of the relevant jurisdiction, or where such offer or invitation does not meet the required conditions under the applicable legislation of the relevant jurisdiction.

Subject to certain limited exceptions, this information and any materials distributed in connection with this information are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or located in the United States of America, Australia, Canada, Japan, South Africa or any other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

In each Member State of the European Economic Area other than Belgium (each a "**Relevant Member State"),** this information is only addressed to and is only directed at qualified investors in that Relevant Member State within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended, and any implementing measure in each Relevant Member State of the EEA (the "**Prospectus Regulation**").

In Switzerland, this information is directed only at persons qualifying as “professional clients” in accordance with Article 4 iuncto 36 of the Swiss Financial Services Act (“**Finanzdienstleistungsgesetz**”) of 15 June 2018, as amended (“**FinSA**”). Any investment activity to which this document relates will only be available to and will only be engaged in with, such professional clients. Any person who is not such a professional client should not act or rely on this document or any of its contents. The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

In the United Kingdom, this information is directed only at “qualified investors” as defined in Article 2(e) of the Prospectus Regulation, as amended and transposed into the laws of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 and the European Union (Withdrawal Agreement) Act 2020 who also have the capacity of (i) persons having professional experience in matters relating to investments falling within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “**Order**”), (ii) high net worth entities, etc. falling within Article 49(2)(a) to (d) of the Order, and (iii) any other person to whom it may otherwise lawfully be communicated. Any investment activity to which this document relates will only be available to and will only be engaged in with, such qualified investors. No person who is not such a qualified investor may act or rely on this document or any of its contents.

Any failure to comply with these restrictions may constitute a violation of the laws or regulations of the United States of America, Australia, Canada, Japan, South Africa, Switzerland, the United Kingdom, or any other jurisdiction. The distribution of this information in other jurisdictions than Belgium, may be restricted by laws or regulations applicable in such jurisdictions. All persons in possession of this information must inform themselves about, and comply with, any such restrictions.

An investment in shares entails significant risks. Relevant investors are encouraged to read the Prospectus (and any documents referred to therein) that is made available on the website of the Company, www.carepropertyinvest.be.

Potential investors should read the Information Document (and any documents referred to therein) prior to making an investment decision, in order to obtain a full understanding of the potential risks and returns associated with the decision to invest in the securities.

For any additional information, please contact:

care property invest

Patrick Couttenier
CEO - Executive director
patrick.couttenier@carepropertyinvest.be
T +32 3 222 94 94 - M +32 478 88 30 49
Horstebaan 3, 2900 Schoten
info@carepropertyinvest.be
www.carepropertyinvest.be

care property invest

Filip Van Zeebroeck
CFO - Executive director
filip.vanzeebroeck@carepropertyinvest.be
T +32 3 222 94 94 - M +32 494 91 10 93
Horstebaan 3, 2900 Schoten
info@carepropertyinvest.be
www.carepropertyinvest.be

care property invest

Willem Van Gaver
CLO
willem.vangaver@carepropertyinvest.be
T +32 3 222 94 94 - M +32 498 41 61 43
Horstebaan 3, 2900 Schoten
info@carepropertyinvest.be
www.carepropertyinvest.be

About Care Property Invest

Care Property Invest NV/SA is a Public Regulated Real Estate Company (public RREC) under Belgian law. The Company has been listed on Euronext Brussels for 30 years and invests in high quality healthcare real estate for elderly and disabled people on the European market. Care Property Invest purchases, builds and renovates high-quality healthcare real estate (residential care centres, groups of assisted living apartments, residential complexes for people with a disability, etc.), fully tailored to the needs of the end user and then makes it available to solid healthcare operators on the basis of a long-term contract.

The Company is developing an international portfolio of healthcare projects, which currently counts 159 projects, spread across Belgium, The Netherlands, Spain and Ireland.

The market capitalisation of Care Property Invest amounted to approximately €445 million on 2 December 2025. The Company aims to create a stable share for its shareholders with a low risk profile and a stable and steadily growing dividend.

Ticker:	CPINV
ISIN Code:	BE0974273055
Index listings:	- FTSE EPRA Nareit Developed Global Index - FTSE EPRA Nareit Developed Europe Index - Belgium BEL Mid (Euronext Brussels) - Euronext Real Estate (Euronext Brussels) - GPR (Global Property Research) General Europe Index -
EPRA:	EPRA member since December 2016. In September 2025, the Company received its ninth EPRA BPR Gold Award.
Website:	All further information can be found on our website, www.carepropertyinvest.be.